RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > Deal or No Deal: Corporate and Regulatory Due Diligence Considerations

Deal or No Deal: Corporate and Regulatory Due Diligence Considerations

Posted 01 July 2009 | By

Deals in the pharmaceutical and medical device industries come fast and furiously, frequently with urgent deadlines. Whether the transaction relates to a co-promotion, licensing, contract manufacturing, divesture or acquisition, thorough and focused due diligence is necessary to minimize surprises, which can be very costly. It is also important to recognize that these deals include a critical component not found in a routine commercial transaction in an unregulated industry: the product or company at issue is regulated by the US Food and Drug Administration (FDA) and regulatory issues must be carefully considered.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe